About: Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.57 (-2.56%)
Last Price
Change (24hr)
AUD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 2:25 pm GMT+0
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Market cap
N/A
ASX rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 2:25 pm GMT+0
NYR Market Signals